Scientific Director of IBCRF Presents The Long-Term Results Of A Landmark IBCRF Study, Chicago, June 2, 2007
June 2007
(Chicago, IL.) - Dr. Richard Love, Scientific director of IBCRF, today presented the long-term results of a landmark IBCRF study of surgical oophorectomy (ovary removal) and tamoxifen as adjuvant treatment for operable breast cancer in premenopausal women. The findings are that after 10 years, compared to no adjuvant therapy, this safe treatment saved 18% of women regardless of whether their tumors were tested for hormonal receptors and 33% of those with tumors with hormonal receptors. The magnitude of the survival benefit in women whose tumors had hormonal receptors is equivalent to that seen with usual adjuvant chemotherapy and hormonal therapy given in the United States.
IBCRF Scientific Director Receives Grant for Breast Cancer Study from BCRF, New York, October 17, 2006
October 2006
(New York, NY.) - The Breast Cancer Research Foundation signature event, the Symposium and Awards Luncheon at
the Waldorf Astoria on Tuesday, October 17th in New York City was a huge success. Grants of $24.3 million
were announced
to 115 stellar researchers worldwide, including IBCRF Scientific Director, Dr. Richard R. Love. To
read more about Dr.
Love’s project visit http://www.bcrfcure.org/rese_meet_love.html.
IBCRF Scientific Director to Present at Oncology World Congress, New York, November 19, 2005
November 2005
(Madison, WI.)— Dr. Richard Love will offer a presentation on adjuvant hormonal therapies for premenopausal women with breast cancer at this meeting. He will note the IBCRF breakthrough findings suggesting that luteal phase oophorectomy is more effective than oophorectomy at other times in the menstrual cycle, highlight the ongoing IBCRF studies looking at this issue, and present updated economic data from Dr. Bruce Hillner on the remarkable cost effectiveness of this approach for 450,000 poor women in the world annually.
